Nymox CEO Paul Averback said, "Final completion of enrollment in this last major pivotal U.S. study is an important milestone in the NX-1207 development pathway. We look forward to reporting further news."
Top-line results are anticipated in early 2014.
In a series of blinded controlled multi-centre trials conducted across the US, a single dose of NX-1207 demonstrated approximately a double of average symptomatic improvements than existing BPH drugs without causing sexual or cardiovascular side effects.
NX-1207 is also being evaluated in Phase 2 study to directly administer it into the area of the prostate to treat low risk localized prostate cancer.